Tandem Diabetes Care (TNDM) Stock Price, News & Analysis

Company Overview

Tandem Diabetes Care, Inc. is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to work with continuous glucose monitoring (CGM) systems and digital health tools to help automate and personalize insulin therapy.

Tandem’s product portfolio includes the t:slim X2 insulin pump, which features a rechargeable design and software that supports automated insulin delivery. The company also offers the t:slim X2 pump with Control-IQ technology, an algorithm designed to adjust insulin delivery based on CGM readings, and the compact Tandem Mobi pump. Its t:connect diabetes management platform supports data collection, remote monitoring and therapy management for patients and healthcare providers.

Founded in 2006 and headquartered in San Diego, California, Tandem Diabetes Care serves customers in the United States and international markets through direct commercial operations and distribution partners. The company’s products are intended for use by people with insulin-dependent diabetes, including individuals with type 1 diabetes. John Sheridan serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $16.14 to $17.25
• 50-Day Range: $15.22 to $23.73
• 52-Week Range: $12.26 to $29.65
• Volume: 1.63 million shs
• Average Volume: 2.34 million shs
• Market Capitalization: $1.13 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.08
• Consensus Rating: Hold

Tandem Diabetes Care Stock Analysis - MarketRank™

Tandem Diabetes Care scored higher than 51% of companies evaluated by MarketBeat, and ranked 545th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Tandem Diabetes Care has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 1 strong buy rating, 9 buy ratings, 12 hold ratings, and 1 sell rating.

Upside Potential

Tandem Diabetes Care has a consensus price target of $27.08, representing about 66.7% upside from its current price of $16.24.

Amount of Analyst Coverage

Tandem Diabetes Care has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tandem Diabetes Care are expected to grow in the coming year, from ($0.66) to $0.09 per share.

Price to Book Value per Share Ratio

Tandem Diabetes Care has a P/B Ratio of 7.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.63% of the float of Tandem Diabetes Care has been sold short.

Short Interest Ratio / Days to Cover

Tandem Diabetes Care has a short interest ratio ("days to cover") of 5.25.

Change versus previous month

Short interest in Tandem Diabetes Care has recently increased by 7.17%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tandem Diabetes Care does not currently pay a dividend.

Dividend Growth

Tandem Diabetes Care does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.33

News Sentiment

Tandem Diabetes Care has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Tandem Diabetes Care this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for TNDM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tandem Diabetes Care insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.10% of the stock of Tandem Diabetes Care is held by insiders.

Percentage Held by Institutions

Tandem Diabetes Care has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:TNDM
• CIK: 1438133
• Web: www.tandemdiabetes.com
• Phone: (858) 366-6900
• Fax: N/A
• Employees: 2,500
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Tandem Diabetes Care: $27.08
• High Price Target: $50.00
• Low Price Target: $15.50
• Potential Upside/Downside: +66.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 23 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$204.71 million
• Net Margins: -6.08%
• Pretax Margin: -5.86%
• Return on Equity: -45.97%
• Return on Assets: -6.23%

Debt

• Debt-to-Equity Ratio: 4.62
• Current Ratio: 3.18
• Quick Ratio: 2.65

Sales & Book Value

• Annual Sales: $1.01 billion
• Price / Sales: 1.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.29 per share
• Price / Book: 7.09

Miscellaneous

• Outstanding Shares: 69,580,000
• Free Float: 68,118,000
• Market Cap: $1.13 billion
• Optionable: Optionable
• Beta: 1.66